| Literature DB >> 34389198 |
Glaivy Batsuli1, Peter Kouides2.
Abstract
Although rare clotting factor deficiencies primarily referred to as rare bleeding disorders (RBD), including factors II, V, VII, and X, make up ∼5% of all inherited bleeding disorders worldwide, each of these clotting factors play a critical role in the coagulation cascade. Incomplete bleeding evaluation or misinterpretation of laboratory studies can result in delayed diagnoses that ultimately affect patient outcomes. Bleeding manifestations can range from mild to severe, but the most common are mucocutaneous bleeding. The ideal treatment in RBD is dedicated single-factor concentrates that can be used for acute bleeding events, surgical management, and prophylaxis.Entities:
Keywords: Epistaxis; Factor II; Factor V; Factor VII; Factor X; Heavy menstrual bleeding; Rare bleeding disorders
Mesh:
Substances:
Year: 2021 PMID: 34389198 DOI: 10.1016/j.hoc.2021.07.010
Source DB: PubMed Journal: Hematol Oncol Clin North Am ISSN: 0889-8588 Impact factor: 3.722